Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

390 questions · 476 findings · 30 reviews · Oral Health

No studies found 40 · 8.4%GRADE not reported 290 · 60.9%Very low 82 · 17.2%Low 47 · 9.9%Moderate 17 · 3.6%High 0 · 0%

Dietary supplements (alpha lipoic acid +/- vitamins/lycopene/green tea; hypericum; Catuama; lycopene) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
  • Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomes
    short-term (up to 3 months)
    SoF5 Dietary supplements vs placebo. Symptom relief short-term: insufficient or contradictory evidence regarding benefit of any evaluated dietary supplement; 628 participants (12 RCTs); very low. Subgroups: ALA without…
    12 studies · 628 participants
    Very low

Topical treatments (benzydamine hydrochloride oral rinse) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
  • Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomes
    short-term (up to 3 months) · benzydamine hydrochloride
    SoF9 Topical treatments vs placebo. Symptom relief short-term: insufficient or contradictory evidence regarding benefit of any evaluated topical treatment; 150 participants (4 RCTs); very low. Subgroups: benzydamine (1…
    4 studies · 150 participants
    Very low

Benzodiazepines (topical clonazepam) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether benzodiazepines (topical clonazepam) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).

2 findings from 1 review

Anticonvulsants (gabapentin 300 mg/day, +/- alpha lipoic acid) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether anticonvulsants (gabapentin 300 mg/day, +/- alpha lipoic acid) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).

1 finding from 1 review

CBT vs No special instructions (control)

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · Adults undergoing orthodontic treatment

Cognitive behavioural therapy (CBT) led to lower patient‐reported pain intensity or pain relief (VAS, NRS or… compared with no special instructions (control); GRADE not reported.

3 findings from 1 review

Low‐level laser therapy vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether electromagnetic radiation (low-level laser therapy) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).

1 finding from 1 review

Low‐level laser therapy vs Placebo (or no irradiation)

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · Adolescents and adults undergoing orthodontic treatment

Low‐level laser therapy (LLLT) showed no clear difference in patient‐reported pain intensity or pain relief (VAS, NRS or… compared with placebo (or no irradiation); GRADE not reported.

5 findings from 1 review
Show 2 more findings

Experimental chewing adjuncts (bite wafers or chewing gum) vs No chewing gum, placebo, or control (no adjunct)

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · Adolescents/teenagers undergoing orthodontic treatment

Experimental chewing adjuncts (bite wafers or chewing gum) showed no clear difference in patient‐reported pain intensity or pain relief (VAS, NRS or… compared with no chewing gum, placebo, or control (no adjunct); GRADE not reported.

5 findings from 1 review
Show 2 more findings

Benzodiazepines (systemic clonazepam 0.5 mg/day) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether benzodiazepines (systemic clonazepam 0.5 mg/day) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).

1 finding from 1 review

Post‐treatment communication (text messaging) vs No communication (no text message)

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)
1 finding from 1 review

Vibratory stimulation (vibratory adjuncts) vs No vibration or placebo vibration

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · Adolescents and adults undergoing orthodontic treatment

Vibratory stimulation (vibratory adjuncts) showed no clear difference in patient‐reported pain intensity or pain relief (VAS, NRS or… compared with no vibration or placebo vibration; GRADE not reported.

5 findings from 1 review
Show 2 more findings

Brain wave music (BWM) vs No special instructions (control)

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · Adults undergoing orthodontic treatment

Brain wave music (BWM) showed no clear difference in patient‐reported pain intensity or pain relief (VAS, NRS or… compared with no special instructions (control); GRADE not reported.

3 findings from 1 review

Cholinergics (bethanechol 15 mg/day) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether cholinergics (bethanechol 15 mg/day) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).

1 finding from 1 review

Psychological therapies (cognitive therapy) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether psychological therapies (cognitive therapy) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).

1 finding from 1 review

Topical treatments (capsaicin oral rinse) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
2 findings from 1 review
  • Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomes
    short-term (up to 3 months) · capsaicin oral rinse
    Capsaicin oral rinse (Marino 2010; Silvestre 2012) contributes to the topical treatments short-term symptom-relief comparison (insufficient/contradictory). Silvestre 2012 data not presented due to 23% first-phase…
    1 study
    GRADE not reported
  • Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomes
    long-term (>3 to 6 months) · capsaicin oral rinse
    MD -2.60 [-5.11, -0.09]
    1 study · 18 participants
    Very low

Amisulpride (antipsychotic, 50 mg/day) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
  • Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomes
    short-term (up to 3 months)
    Bogetto 1999 (amisulpride) included in the antidepressants/antipsychotics comparison but data not presented due to excessive attrition (19/24; 79%) in the placebo arm.
    1 study
    GRADE not reported

Psychological intervention: structured telephone call (verbal follow‐up and reassurance) vs placebo or no intervention

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)

The review found no eligible studies for this question.

1 finding from 1 review